• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Syneos Health Appoints Two New Independent Directors

    1/18/22 6:16:16 AM ET
    $CTS
    $SYNH
    $TPTX
    Electrical Products
    Technology
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $CTS alert in real time by email

    MORRISVILLE, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors.

    "We are excited to welcome Barbara and Alfonso to the Syneos Health Board," said John Dineen, Chair of the Syneos Health Board of Directors. "Barbara's deep financial expertise combined with Alfonso's expansive industry knowledge and international experience bring important perspectives to an already strong Board. These two leaders will enhance the composition of our Board and support continued successful oversight of our strategy as we speed our customers' delivery of important therapies to patients."

    Following the appointment of Ms. Bodem and Mr. Zulueta, the Syneos Health Board is comprised of 11 directors, 10 of whom are independent. Ms. Bodem will serve as a Class I director and will serve on the Company's Audit Committee and Mr. Zulueta will serve as a Class III director.

    Barbara W. Bodem

    Ms. Bodem served as the Senior Vice President and Chief Financial Officer at Hillrom, a global medical technology company, from 2018 until its acquisition by Baxter International Inc. in 2021. She previously served as the Senior Vice President of Finance at Mallinckrodt Pharmaceuticals, a pharmaceutical manufacturer, from 2015 to 2018. She has also served in senior finance roles for Hospira, Inc. and Eli Lilly and Company.

    Ms. Bodem currently serves on the board of directors of Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company, where she serves as Chair of the Audit Committee and as a member of the Compensation Committee. She received both her Bachelor of Science in Finance and MBA from Indiana University.

    Alfonso G. Zulueta

    Mr. Zulueta has over three decades of experience in global strategic and leadership roles within large pharma, specifically with Eli Lilly and Company. At Eli Lilly, he held key senior positions including Vice President of Global Marketing, President of Global Oncology and Critical Care Products, and most recently as President of International responsible for all geographies outside the United States and Canada from 2017 until his retirement at the end of 2021. He was a corporate officer and member of Eli Lilly and Company's executive committee.

    Mr. Zulueta currently serves on the board of directors of CTS Corporation (NYSE:CTS), a global manufacturer of sensors, connectivity components, and actuators, where he serves on the Audit Committee; Compensation Committee; and Nominating, Governance, and Sustainability Committee. He also previously served as a member of the board of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and US-Japan Business Council. He received his Bachelor of Arts from De La Salle University in the Philippines, and his MBA from Colgate Darden Graduate School of Business Administration at the University of Virginia.

    About Syneos Health

    Syneos Health® (NASDAQ:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically blending clinical development, medical affairs and commercial capabilities to address modern market realities.

    We bring together approximately 28,000 minds, across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers' delivery of important therapies to patients.

    Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

    To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

    Investor Relations Contact:Press/Media Contact:
    Ronnie SpeightGary Gatyas
    Senior Vice President, Investor RelationsExecutive Director, External Communications
    +1 919 745 2745+1 908 763 3428
    [email protected][email protected]



    Primary Logo

    Get the next $CTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTS
    $SYNH
    $TPTX

    CompanyDatePrice TargetRatingAnalyst
    CTS Corporation
    $CTS
    2/7/2024$46.00Buy → Neutral
    Sidoti
    CTS Corporation
    $CTS
    2/7/2024$38.00 → $46.00Market Perform
    TD Cowen
    Syneos Health Inc.
    $SYNH
    2/13/2023$30.00 → $28.00Neutral → Underweight
    JP Morgan
    Syneos Health Inc.
    $SYNH
    1/17/2023$30.00 → $25.00Overweight → Underweight
    Barclays
    Syneos Health Inc.
    $SYNH
    1/13/2023$25.00Overweight → Underweight
    Barclays
    Syneos Health Inc.
    $SYNH
    12/14/2022$66.00 → $38.00Buy → Neutral
    Mizuho
    CTS Corporation
    $CTS
    11/22/2022$44.00Hold
    Jefferies
    Syneos Health Inc.
    $SYNH
    11/7/2022$55.00 → $27.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $CTS
    $SYNH
    $TPTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CTS Announces First Quarter 2025 Results

      LISLE, Ill., April 30, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced first quarter 2025 results. "Our global teams continued to execute well in a challenging operating environment. We delivered double digit sales growth in our diversified markets," said Kieran O'Sullivan, CEO of CTS Corporation. "Additionally, we had strong bookings in the quarter in the medical, aerospace and defense, and industrial markets. Diversification remains a strategic priority as we focus on growing our revenues and quality of earnings, both organically and through strategic acquisitio

      4/30/25 8:00:00 AM ET
      $CTS
      Electrical Products
      Technology
    • CTS Corporation Announces Date for First Quarter 2025 Earnings Release and Conference Call

      LISLE, Ill., April 21, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS) will release its earnings for the first quarter 2025 at approximately 8:00 a.m. (ET) on Wednesday, April 30, 2025. A conference call to discuss first quarter 2025 results with management is scheduled for Wednesday, April 30, 2025 at 10:00 a.m. (ET). The dial-in numbers for access from the U.S. are: +1-833-470-1428 (Toll-Free) and +1-404-975-4839 (Local), if calling from outside the U.S., please refer to Global Dial In Numbers to identify the applicable dial-in number for your location. The passcode is 971790. A live audio webcast of the conference call will be available and can be accessed directly from the Invest

      4/21/25 7:30:00 PM ET
      $CTS
      Electrical Products
      Technology
    • CTS Corporation Declares a Dividend

      LISLE, Ill., Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of CTS Corporation (NYSE:CTS) has declared a cash dividend of $0.04 per share on outstanding shares of common stock, without par value, to be paid on April 25, 2025, to shareholders of record at the close of business on March 28, 2025. About CTS CTS Corporation (NYSE:CTS) is a leading designer and manufacturer of products that Sense, Connect and Move. CTS manufactures sensors, actuators and electronic components in North America, Europe and Asia, and provides engineered products to customers in the aerospace/defense, industrial, medical and transportation markets. For more information, visit www.ctscorp.com. Contact

      2/6/25 6:00:00 PM ET
      $CTS
      Electrical Products
      Technology

    $CTS
    $SYNH
    $TPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO O'Sullivan Kieran M covered exercise/tax liability with 10,374 shares, decreasing direct ownership by 2% to 414,410 units (SEC Form 4)

      4 - CTS CORP (0000026058) (Issuer)

      2/11/25 3:55:34 PM ET
      $CTS
      Electrical Products
      Technology
    • CFO Agrawal Ashish covered exercise/tax liability with 2,762 shares, decreasing direct ownership by 2% to 130,987 units (SEC Form 4)

      4 - CTS CORP (0000026058) (Issuer)

      2/11/25 3:52:56 PM ET
      $CTS
      Electrical Products
      Technology
    • VP & Secretary D'Angelo Scott covered exercise/tax liability with 1,989 shares, decreasing direct ownership by 6% to 30,100 units (SEC Form 4)

      4 - CTS CORP (0000026058) (Issuer)

      2/11/25 3:50:58 PM ET
      $CTS
      Electrical Products
      Technology

    $CTS
    $SYNH
    $TPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CTS Corp downgraded by Sidoti with a new price target

      Sidoti downgraded CTS Corp from Buy to Neutral and set a new price target of $46.00

      2/7/24 8:52:47 AM ET
      $CTS
      Electrical Products
      Technology
    • TD Cowen reiterated coverage on CTS Corp with a new price target

      TD Cowen reiterated coverage of CTS Corp with a rating of Market Perform and set a new price target of $46.00 from $38.00 previously

      2/7/24 7:05:38 AM ET
      $CTS
      Electrical Products
      Technology
    • Syneos Health downgraded by JP Morgan with a new price target

      JP Morgan downgraded Syneos Health from Neutral to Underweight and set a new price target of $28.00 from $30.00 previously

      2/13/23 7:39:42 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CTS
    $SYNH
    $TPTX
    Leadership Updates

    Live Leadership Updates

    See more
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • CTS Corporation Announces Appointment of Amy M. Dodrill to its Board of Directors

      LISLE, Ill., Feb. 08, 2024 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced that Amy M. Dodrill has been appointed to its board of directors, effective February 8, 2024, and will serve as a member of the nominating, governance and sustainability and technology and transactions committees. Ms. Dodrill comes to CTS with over 25 years of experience in medical and technology companies and a proven track record of successfully leading and profitably growing global businesses serving key end markets. Ms. Dodrill most recently served as President of Baxter's Global Surgical

      2/8/24 5:30:00 PM ET
      $CTS
      $PRCT
      Electrical Products
      Technology
      Medical/Dental Instruments
      Health Care
    • Civitas Resources Set to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600

      NEW YORK, Sept. 26, 2023 /PRNewswire/ -- S&P SmallCap 600 constituent Civitas Resources Inc. (NYSE:CIVI) will replace Syneos Health Inc. (NASD: SYNH) in the S&P MidCap 400, and Hayward Holdings Inc. (NYSE:HAYW) will replace Civitas Resources in the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 29. Elliot Investment Management is acquiring Syneos Health in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector September 29, 2023 S&P MidCap 400 Addition Civitas Resources

      9/26/23 5:41:00 PM ET
      $CIVI
      $HAYW
      $SPGI
      $SYNH
      Oil & Gas Production
      Energy
      Industrial Machinery/Components
      Industrials

    $CTS
    $SYNH
    $TPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CTS Corporation

      SC 13G/A - CTS CORP (0000026058) (Subject)

      11/14/24 1:28:29 PM ET
      $CTS
      Electrical Products
      Technology
    • SEC Form SC 13G filed by CTS Corporation

      SC 13G - CTS CORP (0000026058) (Subject)

      11/14/24 12:28:26 PM ET
      $CTS
      Electrical Products
      Technology
    • SEC Form SC 13G/A filed by CTS Corporation (Amendment)

      SC 13G/A - CTS CORP (0000026058) (Subject)

      2/14/24 10:04:36 AM ET
      $CTS
      Electrical Products
      Technology

    $CTS
    $SYNH
    $TPTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by CTS Corporation

      10-Q - CTS CORP (0000026058) (Filer)

      4/30/25 1:55:55 PM ET
      $CTS
      Electrical Products
      Technology
    • CTS Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CTS CORP (0000026058) (Filer)

      4/30/25 8:07:36 AM ET
      $CTS
      Electrical Products
      Technology
    • CTS Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CTS CORP (0000026058) (Filer)

      4/30/25 8:00:22 AM ET
      $CTS
      Electrical Products
      Technology

    $CTS
    $SYNH
    $TPTX
    Financials

    Live finance-specific insights

    See more
    • CTS Announces First Quarter 2025 Results

      LISLE, Ill., April 30, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced first quarter 2025 results. "Our global teams continued to execute well in a challenging operating environment. We delivered double digit sales growth in our diversified markets," said Kieran O'Sullivan, CEO of CTS Corporation. "Additionally, we had strong bookings in the quarter in the medical, aerospace and defense, and industrial markets. Diversification remains a strategic priority as we focus on growing our revenues and quality of earnings, both organically and through strategic acquisitio

      4/30/25 8:00:00 AM ET
      $CTS
      Electrical Products
      Technology
    • CTS Corporation Announces Date for First Quarter 2025 Earnings Release and Conference Call

      LISLE, Ill., April 21, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS) will release its earnings for the first quarter 2025 at approximately 8:00 a.m. (ET) on Wednesday, April 30, 2025. A conference call to discuss first quarter 2025 results with management is scheduled for Wednesday, April 30, 2025 at 10:00 a.m. (ET). The dial-in numbers for access from the U.S. are: +1-833-470-1428 (Toll-Free) and +1-404-975-4839 (Local), if calling from outside the U.S., please refer to Global Dial In Numbers to identify the applicable dial-in number for your location. The passcode is 971790. A live audio webcast of the conference call will be available and can be accessed directly from the Invest

      4/21/25 7:30:00 PM ET
      $CTS
      Electrical Products
      Technology
    • CTS Corporation Declares a Dividend

      LISLE, Ill., Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of CTS Corporation (NYSE:CTS) has declared a cash dividend of $0.04 per share on outstanding shares of common stock, without par value, to be paid on April 25, 2025, to shareholders of record at the close of business on March 28, 2025. About CTS CTS Corporation (NYSE:CTS) is a leading designer and manufacturer of products that Sense, Connect and Move. CTS manufactures sensors, actuators and electronic components in North America, Europe and Asia, and provides engineered products to customers in the aerospace/defense, industrial, medical and transportation markets. For more information, visit www.ctscorp.com. Contact

      2/6/25 6:00:00 PM ET
      $CTS
      Electrical Products
      Technology